Journal: Molecular cancer

Article Title: Next-generation sequencing reveals novel differentially regulated mRNAs, lncRNAs, miRNAs, sdRNAs and a piRNA in pancreatic cancer.

doi: 10.1186/s12943-015-0358-5

Figure Lengend Snippet: Figure 3 Co-expression of miR-802, ZEB1, TCF4 and miR-21. A) Alignment of miR-802 to the predicted binding sites in the 3′ UTR of TCF4. B) Co-expression analysis of significantly upregulated transcription factors that harbour predicted miRNA binding sites in their 3′ UTRs for one of the ten most significantly upregulated miRNAs (miRNAs that have no seed sequence for a TF UTR not shown). Significant (p < 0.01) correlations are indicated by a dot, positive correlations are marked in blue, negative correlations in red. The more significant the correlation, the larger the dot size. Sequence complementarity between an UTR and a miRNA is indicated by an “S”. C) Expression of TCF4, ZEB1 and miR-21 across all control (C) and PDAC (P) samples (significant positive correlation) as well as the expression of miR-802 (significantly inversely correlated). The normalized expression for each gene/miRNA is given in log2-scale for each sample.

Article Snippet: Sections were incubated with the ZEB1 antibody (ZEB1: Atlas Antibodies #AMAb90510 (1:400)) at 4°C overnight followed by incubation with horseradish peroxidase-linked goat anti-mouse antibody, followed by a color-reaction with diaminebenzidine and counterstaining with Mayer’s hematoxylin.

Techniques: Expressing, Binding Assay, Sequencing, Control

Journal: Molecular cancer

Article Title: Next-generation sequencing reveals novel differentially regulated mRNAs, lncRNAs, miRNAs, sdRNAs and a piRNA in pancreatic cancer.

doi: 10.1186/s12943-015-0358-5

Figure Lengend Snippet: Figure 5 Immunohistochemistry of ZEB1 protein expression. Immunohistochemical detection of ZEB1 in human pancreatic tissue samples. Representative images of ZEB1 expression: Upper panels, ZEB1 is expressed in periacinar cells in normal pancreatic tissue samples. Lower panels, detection of ZEB1 in stromal cells, but not in epithelial tumor cells in PDAC samples.

Article Snippet: Sections were incubated with the ZEB1 antibody (ZEB1: Atlas Antibodies #AMAb90510 (1:400)) at 4°C overnight followed by incubation with horseradish peroxidase-linked goat anti-mouse antibody, followed by a color-reaction with diaminebenzidine and counterstaining with Mayer’s hematoxylin.

Techniques: Immunohistochemistry, Expressing, Immunohistochemical staining

Journal: Cancer discovery

Article Title: Direct and Indirect Regulators of Epithelial-Mesenchymal Transition (EMT)-mediated Immunosuppression in Breast Carcinomas

doi: 10.1158/2159-8290.CD-20-0603

Figure Lengend Snippet: (A) Phase contrast images and immunofluorescence analysis of qM control or KO cell lines for the indicated EMT markers. E-cadherin (white), Vimentin or Zeb1 (red), and DAPI (nuclear stain in blue). Scale bar = 20 μm (B) Western Blot analysis of qM control or KO cell lines for the indicated EMT markers. (C) Histogram showing surface levels of Epcam expression in qM control or KO cell lines as determined by flow cytometry. (D) Hemotoxylin and Eosin staining and immunofluorescence staining of tumor sections obtained from qM control or KO-tumor bearing mice stained for the indicated EMT markers. GFP (carcinoma cells in green). E-cadherin (white), Vimentin or Zeb1 (red), and DAPI (nuclear stain in blue) Scale bar = 20 μm. Data represent three independent experiments.

Article Snippet: Primary antibodies used were E-cadherin, Vimentin, Zeb1, Snail, Slug, Sox9, GAPDH, CSF1, Galectin-3, MASP1/3, Fibronectin (BD Biosciences) Cytokine Arrays.

Techniques: Immunofluorescence, Staining, Western Blot, Expressing, Flow Cytometry